Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gene Therapy Drug May Show Promise In Treatment Of Huntington’s Disease

XTALKS VITALS NEWS

Wal-Mart

A novel gene therapy drug developed by antibody company Vybion, has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease.

Tweetables from this article:

Tweet: The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease http://ctt.ec/d9KhBThe drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease.

Share this!

September 1, 2016 | by Sarah Massey, M.Sc.

A novel gene therapy drug developed by antibody company Vybion has been shown to block cellular gene dysregulation and delay cognitive and motor problems associated with Huntington’s disease. The details of the intrabody drug INT41, an antibody that binds to an intracellular protein, were published in the Journal of Neurodegenerative Diseases.

INT41 prevents toxic N-terminal huntingtin fragments from being transported into the nucleus of the cell and blocks them from binding with the DNA. The drug was tested in the well-validated R6/2 mouse model of Huntington’s disease.

“We believe that our therapeutic approach to the treatment of Huntington's disease has provided a biological rationale linking Huntington's disease progression and toxic N-terminal fragments,” said Dr. Lee Henderson, CEO of Vybion. “We look forward to completing our plans for human patient trials.”

The drug candidate is currently in late-stage preclinical development for the treatment of Huntington’s disease. Vybion’s proprietary technologies revolve around the discovery and development of intrabody drugs for multiple neurodegenerative diseases.

“The data also demonstrate that Vybion's platform may have broader application in generating intrabody drug candidates to difficult-to-drug targets, including intracellular proteins in neurodegenerative disorders and other disease areas such as oncology,” said a statement released by Vybion. “Further, the platform may be used to validate new targets of interest, particularly in intracellular signal transduction pathways, prior to generation of new therapeutic candidates.”


Keywords: Gene Therapy, Huntington's Disease, Drug Development


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.